GlassScriptPhysician profile
Michelle L Evans
NPI 1952631988
$8,547.68
in general payments reported to CMS, 2019-2025
30 companies · $2,102 in 2025
The $2,102 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,283 · 2022: $1,600 · 2023: $1,512 · 2024: $2,051 · 2025: $2,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,405 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,404.97 |
| Education | $259.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,891.96 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,254.87 | 2021-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $878.38 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $676.02 | 2021-2025 | Dupixent |
| Amgen INC. | $657.78 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $650.20 | 2022-2025 | |
| Ucb, INC. | $396.16 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $283.79 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $268.48 | 2021-2025 | Jublia, Arazlo, Cabtreo |
| Incyte Corporation | $268.37 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $192.56 | 2022-2025 | Adbry, Spevigo |
| Epi Health, LLC | $190.24 | 2021-2022 | |
| Pfizer INC. | $129.80 | 2021-2025 | |
| Galderma Laboratories, L.P. | $129.75 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $120.72 | 2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.32 | 2023-2025 | Spevigo |
| Lilly USA, LLC | $95.71 | 2021-2023 | Taltz, Olumiant |
| Mayne Pharma Commercial LLC | $78.47 | 2022-2023 | |
| Mylan Institutional INC. | $39.61 | 2023 | Hulio |
| E.R. Squibb & Sons, L.L.C. | $28.98 | 2025 | Sotyktu |
| Fresenius Kabi USA, LLC | $25.66 | 2024 | Idacio |
| Biocon Biologics INC | $24.42 | 2025 | Yesintek |
| Sensus Healthcare, INC. | $24.00 | 2021 | |
| Verrica Pharmaceuticals INC. | $23.89 | 2023 | Ycanth |
| Journey Medical Corporation | $18.49 | 2022 | |
| Almirall LLC | $18.23 | 2025 | Klisyri |
| Organon LLC | $16.50 | 2023 | Hadlima |
| Biofrontera INC. | $16.16 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Pharmacosmos Therapeutics INC. | $15.95 | 2025 | Monoferric |
| Vyne Pharmaceuticals INC. | $13.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.